Working with clinical professionals teaching and informing around uniquely specified devices to surgically treat intractable atrial fibrillation, atrial blood stagnation and stroke risk, and a host of health altering cardiac arrhythmias.My role primarily addresses needs in small incision ("minimally invasive") cardiothoracic incisional surgery, standalone cardiac ablation procedures and related perioperative activites.Active in training and coaching CVT surgeons and CVOR staff in the utilization of specialized devices for novel and leading, evidence-based, surgical therapies for cardiac rhythm issues, left atrial appendage mitigation, and pretreatmet of post-op pain.

Experienced in the medical device and clinical side of cardiothoracic interventional therapy including surgery, interventional device utilization, progressive medical research, and revenue (manufacturing, management, strategy, and planning). More specifically attuned to structural heart mechanics, function, physiology and realted intensive procedures. Well-versed in cardiothoracic surgical techniques, both conventional and small-incision ("minimally invasive"), with vast experience with over-wire procedural techniques and therapies.Highly proficient in imaging technologies and interpretation for diagnostics, intra-procedural guidance and evaluation in flouroscopy, CT, MRI, TEE, TTE, and related methods for diagnostics, evaluation, and cardiothoracic procedural fitness.Experienced in regional and business unit management, exceeding quota performance, business/industry strategy and planning, training (clinical, procedural, and sales/business acumen and strategy), and market evaluation/prediction.

Coaching surgeons and their teams as they ramp up towards proficiency in minimally invasive cardiac surgery. Primarily focused on techniques and approaches to aortic/mitral valve surgery, repair and replacement, and procedures for defect repair, my role in the operating room is one of a consultative nature involving the cardiothoracic surgical team, the surgeon, Perfusion, and the anesthesiologist.Options for treating heart disease are expanded by minimally invasive techniques. Minimal incision valve surgery (MIVS) is one of the most clinically effective heart valve procedures available. With its ThruPort systems, Edwards provides surgeons with integrated solutions that include a complete portfolio of market-leading products, procedural education and expert clinical support. We provide the broadest range of innovative technologies, comprehensive team training, and unrivaled operating room support.Edwards Lifesciences is the global leader in the science of heart valves and hemodynamic monitoring. Driven by a passion to help patients, the company partners with clinicians to develop innovative technologies in the areas of structural heart disease and critical care monitoring that enable them to save and enhance lives.http://www.edwards.com/products/mivs/Pages/MIVS.aspx

Provide relevant information to the key stakeholders in the acquisition process for the Truven Health Analytics products. In concert with strategic Sales and Marketing strategies, complete purchaser/user connections concerning clinical workflow and healthcare information content to assist care provision in hospitals become safer, more accurate, more efficient, with real return on investment.

Traveling all over the US coaching surgeons and their teams as they ramp up towards proficiency in minimally invasive cardiac surgery. Primarily focused on techniques and approaches to mitral valve surgery, repair and replacement, and right heart procedures for defect repair, my role in the operating room is one of a consultative nature involving the cardiac surgical team, the surgeon, Perfusion, and the anesthesiologist.Minimally invasive cardiac surgery, also called Port Access Surgery (a renewal of the HeartPort procedures), involves translocating traditionally wound applied devices such as cannulae for cardiopulmonary bypass, use of peripheral catheters to provide retrograde cardioplegia delivery and pulmonary artery 'venting,' to minimize the incision to gain access to the heart.Edwards Lifesciences has been manufacturing heart valves for 50 years, have 85% of the tissue valve market, and just recently celebrated the 1 millionth valve implant.